Er Stratec udbyttet sikkert?
Stratec har øget udbyttet i 18 år.
Inden for de seneste 10 år har Stratec øget denne med 5,647 % årligt forøget.
På 5-årssigt steg udbetalingen med 3,929 %.
Analytikerne forventer en Dividendeøgning på 4,176% for det igangværende regnskabsår.
Stratec Aktienanalyse
Hvad laver Stratec?
The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments.
Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis.
In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices.
In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics.
Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues.
In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination.
Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success.
In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers.
Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide.
Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec er et af de mest populære virksomheder på Eulerpool.com.Aktiespareplaner tilbyder en attraktiv mulighed for investorer at opbygge formue på lang sigt. En af de største fordele er den såkaldte cost-average-effekt: Ved regelmæssigt at investere et fast beløb i aktier eller aktiefonde, køber man automatisk flere andele, når priserne er lave, og færre, når de er høje. Dette kan føre til en mere fordelagtig gennemsnitspris per andel over tid. Desuden giver aktiespareplaner også småinvestorer adgang til dyre aktier, da de kan deltage med små beløb. Den regelmæssige investering fremmer også en disciplineret investeringsstrategi og hjælper med at undgå følelsesladede beslutninger, som impulsiv køb eller salg. Derudover drager investorer fordel af den potentielle værdistigning af aktierne samt af udbytteudlodninger, der kan geninvesteres, hvilket forstærker renters rente effekten og dermed væksten af det investerede kapital.
Stratec aktien kan indgå i opsparingsplaner hos følgende udbydere: Trade Republic